PreprintArticleVersion 1This version is not peer-reviewed
Development of a New Treatment for Interstitial Lung Disease and COPD with Platinum-Palladium - In Relation to Improvement Examples and Research Examples
Version 1
: Received: 6 September 2024 / Approved: 6 September 2024 / Online: 6 September 2024 (14:42:42 CEST)
How to cite:
Kawakami, S.; Shirakawa, T.; Wajima, S.; Segawa, Y.; Fukuzawa, Y.; Sakabe, K. Development of a New Treatment for Interstitial Lung Disease and COPD with Platinum-Palladium - In Relation to Improvement Examples and Research Examples. Preprints2024, 2024090556. https://doi.org/10.20944/preprints202409.0556.v1
Kawakami, S.; Shirakawa, T.; Wajima, S.; Segawa, Y.; Fukuzawa, Y.; Sakabe, K. Development of a New Treatment for Interstitial Lung Disease and COPD with Platinum-Palladium - In Relation to Improvement Examples and Research Examples. Preprints 2024, 2024090556. https://doi.org/10.20944/preprints202409.0556.v1
Kawakami, S.; Shirakawa, T.; Wajima, S.; Segawa, Y.; Fukuzawa, Y.; Sakabe, K. Development of a New Treatment for Interstitial Lung Disease and COPD with Platinum-Palladium - In Relation to Improvement Examples and Research Examples. Preprints2024, 2024090556. https://doi.org/10.20944/preprints202409.0556.v1
APA Style
Kawakami, S., Shirakawa, T., Wajima, S., Segawa, Y., Fukuzawa, Y., & Sakabe, K. (2024). Development of a New Treatment for Interstitial Lung Disease and COPD with Platinum-Palladium - In Relation to Improvement Examples and Research Examples. Preprints. https://doi.org/10.20944/preprints202409.0556.v1
Chicago/Turabian Style
Kawakami, S., Yoshitaka Fukuzawa and Kou Sakabe. 2024 "Development of a New Treatment for Interstitial Lung Disease and COPD with Platinum-Palladium - In Relation to Improvement Examples and Research Examples" Preprints. https://doi.org/10.20944/preprints202409.0556.v1
Abstract
Interstitial pneumonia is a general term for diseases in which inflammation occurs mainly in the interstitium of the lung. It is also pointed out that interstitial pneumonia reduces alveolar function and makes it difficult to take in oxygen through inspiration, causing symptoms such as dyspnea and coughing, which may eventually lead to respiratory failure. At present, there is no effective treatment and only conservative treatment exists. This time, we report that the therapeutic effect was confirmed in patients with interstitial pneumonia who took platinum-palladium. In this case, improvement tendencies were observed in patients with Idiopathic pulmonary fibrosis (IPF), but improvement tendencies were also observed in many other lung diseases. In order to explore the mechanism, AMPK was measured at the in vitro level, and blood KL-6 and hydrogen peroxide levels in the patient were measured at the in vivo level. AMPK values were significantly elevated by more than 800%, KL-6 and hydrogen peroxide levels were also significantly decreased by drinking platinum-palladium. Platinum-palladium exhibits a strong antioxidant effect and is the only substance in the world that can approach all four types of active oxygen. In addition, when it was actually administered to patients, there were cases of dramatic improvement, and it was confirmed that KL-6, a parameter of lung function, decreased in 16 out of 32 patients As the number of cases is expected to increase in the future, the substance is expected to be effective as a drug, although it is currently classified as a soft drink.
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
